An overview of the efficacy of resveratrol in the management of ischemic heart disease

Annals of the New York Academy of Sciences

Volumn 1348, Issue 1, 2015, Pages 55-67

  Raj, Pema ^a,b   Zieroth, Shelley ^a   Netticadan, Thomas ^a,b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b The Inst of Cardiovascular Sciences   (Canada)

^c AGRICULTURE AND AGRI FOOD CANADA   (Canada)

Author keywords

ischemic heart disease; preclinical and clinical trial studies; resveratrol

Indexed keywords

HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICRORNA; RESVERATROL;

ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR GENE THERAPY; CLINICAL STUDY; COMBINATION DRUG THERAPY; CORONARY ARTERY OCCLUSION; DRUG EFFECT; DRUG EFFICACY; EX VIVO STUDY; GRAPE; HEART PROTECTION; HUMAN; IN VIVO STUDY; ISCHEMIC HEART DISEASE; LONG TERM CARE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; REGENERATIVE MEDICINE; SHORT COURSE THERAPY;

EID: 85006372241     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12828     Document Type: Article

References (59)

1. Roger, V.L. 2013. Epidemiology of heart failure. Circ. Res. 113: 646–659.
2. Finegold, J.A., P. Asaria & D.P. Francis. 2013. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int. J. Cardiol. 168: 934–945.
3. van Oeffelen, A.A. et al. 2014. Prognosis after a first hospitalisation for acute myocardial infarction and congestive heart failure by country of birth. Heart 100: 1436–1443.
4. Weir, R. & J.J. McMurray. 2005. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction. Heart 91(Suppl 2.): ii17–20; discussion ii31, ii43–18.
5. Jhund, P.S. & J.J. McMurray. 2008. Heart failure after acute myocardial infarction: a lost battle in the war on heart failure? Circulation 118: 2019–2021.
6. Fraccarollo, D., P. Galuppo & J. Bauersachs. 2012. Novel therapeutic approaches to post-infarction remodelling. Cardiovasc. Res. 94: 293–303.
7. Mann, D.L. & M.R. Bristow. 2005. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111: 2837–2849.
8. Raj, P. et al. 2014. Potential of resveratrol in the treatment of heart failure. Life Sci. 95: 63–71.
9. Xi, J. et al. 2009. Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore. Eur. J. Pharmacol. 604: 111–116.
10. Thuc, L.C. et al. 2012. Inhibition of Na(+)-H(+) exchange as a mechanism of rapid cardioprotection by resveratrol. Br. J. Pharmacol. 166: 1745–1755.
11. Chen, W.P., M.J. Su & L.M. Hung. 2007. In vitro electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant. Eur. J. Pharmacol. 554: 196–204.
12. Lamont, K.T. et al. 2011. Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J. Pineal. Res. 50: 374–380.
13. Mokni, M. et al. 2013. Resveratrol provides cardioprotection after ischemia/reperfusion injury via modulation of antioxidant enzyme activities. Iran J. Pharm. Res. 12: 867–875.
14. Mokni, M. et al. 2007. Strong cardioprotective effect of resveratrol, a red wine polyphenol, on isolated rat hearts after ischemia/reperfusion injury. Arch. Biochem. Biophys. 457: 1–6.
15. Bradamante, S. et al. 2003. Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism. Eur. J. Pharmacol. 465: 115–123.
16. Liao, Z. et al. 2015. Long-term oral resveratrol intake provides nutritional preconditioning against myocardial ischemia/reperfusion injury: involvement of VDAC1 downregulation. Mol. Nutr. Food Res. 59: 454–464.
17. Shinmura, K. et al. 2015. Indispensable role of endothelial nitric oxide synthase in caloric restriction-induced cardioprotection against ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 308: H894–H903.
18. Lekli, I. et al. 2008. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am. J. Physiol. Heart Circ. Physiol. 294: H859–H866.
19. Thirunavukkarasu, M. et al. 2007. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic. Biol. Med. 43: 720–729.
20. Penumathsa, S.V. et al. 2007. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J. Mol. Cell. Cardiol. 42: 508–516.
21. Shen, M. et al. 2006. Cardioprotective effect of resvaratrol pretreatment on myocardial ischemia-reperfusion induced injury in rats. Vasc. Pharmacol. 45: 122–126.
22. Li, J. et al. 2015. Resveratrol attenuates inflammation in the rat heart subjected to ischemia-reperfusion: role of the TLR4/NF-kappaB signaling pathway. Mol. Med. Rep. 11: 1120–1126.
23. Hung, L.M., M.J. Su & J.K. Chen. 2004. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic. Biol. Med. 36: 774–781.
24. Hung, L.M. et al. 2000. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc. Res. 47: 549–555.
25. Zhang, Y. et al. 2006. Resveratrol, a natural ingredient of grape skin: antiarrhythmic efficacy and ionic mechanisms. Biochem. Biophys. Res. Commun. 340: 1192–1199.
26. Shalwala, M. et al. 2014. Sirtuin 1 (SIRT1) activation mediates sildenafil induced delayed cardioprotection against ischemia-reperfusion injury in mice. PLoS One 9: e86977.
27. Kaga, S. et al. 2005. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J. Mol. Cell. Cardiol. 39: 813–822.
28. Chen, Y.R. et al. 2008. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc. Drugs Ther. 22: 479–485.
29. Fukuda, S. et al. 2006. Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem. Biophys. 44: 43–49.
30. Robich, M.P. et al. 2010. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 122: S142–S149.
31. Robich, M.P. et al. 2012. Resveratrol preserves myocardial function and perfusion in remote nonischemic myocardium in a swine model of metabolic syndrome. J. Am. Coll. Surg. 215: 681–689.
32. Lin, J.F. et al. 2008. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci. 83: 313–317.
33. Xuan, W. et al. 2012. Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine. Crit. Care Med. 40: 3026–3033.
34. Gu, X.S. et al. 2014. Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. Genet. Mol. Res. 13: 323–335.
35. Kanamori, H. et al. 2013. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am. J. Pathol. 182: 701–713.
36. Hale, S.L. & R.A. Kloner. 2001. Effects of resveratrol, a flavinoid found in red wine, on infarct size in an experimental model of ischemia/reperfusion. J. Stud. Alcohol 62: 730–735.
37. Burstein, B. et al. 2007. Effects of resveratrol (trans-3,5,4’-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. J. Pharmacol. Exp. Ther. 323: 916–923.
38. Garbern, J.C. & R.T. Lee. 2013. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 12: 689–698.
39. Bernstein, H.S. & D Srivastava. 2012. Stem cell therapy for cardiac disease. Pediatr. Res. 71: 491–499.
40. Wang, H. et al. 2012. Statin administration does not improve the mobilization of very small embryonic-like stem cells (VSELs) in contrast to resveratrol treatment in a murine model of acute myocardial infarction. Physiol. Res. 61: 543–549.
41. Avolio, E. et al. 2014. Ex vivo molecular rejuvenation improves the therapeutic activity of senescent human cardiac stem cells in a mouse model of myocardial infarction. Stem Cells 32: 2373–2385.
42. van Rooij, E., A. L. Purcell & AA. Levin. 2012. Developing microRNA therapeutics. Circ. Res. 110: 496–507.
43. Tili, E. & J.J. Michaille. 2011. Resveratrol, microRNAs, inflammation, and cancer. J. Nucleic Acids 2011: 102431.
44. Mukhopadhyay, P. et al. 2012. Modulation of microRNA 20b with resveratrol and longevinex is linked with their potent anti-angiogenic action in the ischaemic myocardium and synergestic effects of resveratrol and gamma-tocotrienol. J. Cell. Mol. Med. 16: 2504–2517.
45. Mukhopadhyay, P. et al. 2010. Restoration of altered microRNA expression in the ischemic heart with resveratrol. PLoS One 5: e15705.
46. Tome-Carneiro, J. et al. 2013. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res. 72: 69–82.
47. 2+-ATPase in patients with advanced heart failure. Circulation 124: 304–313.
48. Bickenbach, K.A. et al. 2008. Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther. 15: 133–139.
49. Zordoky, B.N., I.M. Robertson & J.R. Dyck. 2015. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim. Biophys. Acta 1852: 1155–1177.
50. Hori, M. & K. Nishida. 2009. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc. Res. 81: 457–464.
51. Xin, P. et al. 2010. Favorable effects of resveratrol on sympathetic neural remodeling in rats following myocardial infarction. Eur. J. Pharmacol. 649: 293–300.
52. Brunner, F. et al. 2003. Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc. Res. 57: 55–62.
53. Schulz, R., M. Kelm & G. Heusch. 2004. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc. Res. 61: 402–413.
54. Chong, E. et al. 2015. Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation. Heart Rhythm 12: 1046–1056.
55. Magyar, K. et al. 2012. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 50: 179–187.
56. Rogoveanu, O.C. et al. 2015. Effects of calcium fructoborate on levels of c-reactive protein, total cholesterol, low-density lipoprotein, triglycerides, IL-1beta, IL-6, and MCP-1: a double-blind, placebo-controlled clinical study. Biol. Trace Element Res. 163: 124–131.
57. Militaru, C. et al. 2013. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition 29: 178–183.
58. Tome-Carneiro, J. et al. 2012. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol. 110: 356–363.
59. Tome-Carneiro, J. et al. 2013. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 27: 37–48.